Evidence map›Paper›PMID 32213479›Full record

ArticleJMIR research protocols2020

Evaluating Mobile Apps and Biosensing Devices to Monitor Physical Activity and Respiratory Function in Smokers With and Without Respiratory Symptoms or Chronic Obstructive Pulmonary Disease: Protocol for a Proof-of-Concept, Open-Label, Feasibility Study.

Almaz Sharman, Baurzhan Zhussupov, Dana Sharman, Irina Kim

Registry-linked trialAbstract read
In one paragraph

Article in JMIR research protocols, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04081961 (A Proof-of-concept, Open-label, Feasibility Study to Evaluate Mobile Applications and Biosensing), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04081961 completednot on this map

A Proof-of-concept, Open-label, Feasibility Study to Evaluate Mobile Applications and Biosensing (mHealth) Devices to Monitor Physical Activity and Respiratory Function in Smokers With and Without Respiratory Symptoms/COPD

TypeobservationalSponsorKazakhstan Academy of Preventive MedicineRan2019 to 2019Enrolled27ConditionsSigns and Symptoms, Respiratory, Mobile Applications, Activity Trackers, Respiratory Function TestsArmsAnamed OEM device, Air Next mobile spirometry device
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Almaz SharmanKazakhstan Academy of Preventive Medicine, Almaty, Kazakhstan.ORCID https://orcid.org/0000-0003-3977-3636
Baurzhan ZhussupovKazakhstan Academy of Preventive Medicine, Almaty, Kazakhstan.ORCID https://orcid.org/0000-0002-8240-2753
Dana SharmanKazakhstan Academy of Preventive Medicine, Almaty, Kazakhstan.ORCID https://orcid.org/0000-0002-6845-4602
Irina KimSynergy Research Group Kazakhstan, Almaty, Kazakhstan.ORCID https://orcid.org/0000-0001-5852-0883

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) is a global public health problem, and continuous monitoring is essential for both its management as well as the management of other chronic diseases. Telemonitoring using mobile health (mHealth) devices has the potential to promote self-management, improve control, increase quality of life, and prevent hospital admissions.

objectiveThis study aims to demonstrate whether a large-scale study assessing the use of mHealth devices to improve the treatment, assessment, compliance, and outcomes of chronic diseases, particularly COPD and cardio-metabolic syndrome, is feasible. This will allow our team to select the appropriate design and characteristics for our large-scale study.

methodsA total of 3 cohorts, with 9 participants in each, will use mHealth devices for 90 days while undergoing the current standard of care. These groups are: 9 "non-COPD," otherwise healthy, smokers; 9 "grey zone" smokers (forced expiratory volume in 1 second/ forced vital capacity ≥0.70 after bronchodilator treatment; COPD Assessment Test ≥10); and 9 smokers diagnosed with Stage 1-3 COPD. Rates of recruitment, retention, and adherence will be measured. Overall, two mHealth devices will be utilized in the study: the AnaMed Original Equipment Manufacturer device (measures distance, energy expenditure, heart rate, and heart rate variability) and the Air Next mobile spirometry device. The mHealth devices will be compared against industry standards. Additionally, a questionnaire will be administered to assess the participants' perceptions of the mHealth technologies used.

resultsThe inclusion of participants started in June 2019. Study results will be published in peer-reviewed scientific journals.

conclusionsThis study will demonstrate whether a large-scale study to assess the use of mHealth devices to improve the treatment, assessment, compliance, and outcomes of chronic diseases, particularly COPD and cardio-metabolic syndrome, is feasible. It will also allow the research team to select the appropriate design and characteristics for the large-scale study.

trial registrationClinicalTrials.gov NCT04081961; https://clinicaltrials.gov/ct2/show/NCT04081961. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/16461.

Indexed as

COPDfeasibility studymHealthmobile health appssmokers

Identifiers

PMID32213479
PMCPMC7146253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.